Trial · NCT04335721
A Voxelotor for Sickle Cell Anemia Patients at Highest Risk for Progression of Chronic Kidney Disease
NCT04335721, Phase 1, Phase 2, Terminated, University of Illinois Chicago
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Voxelotor for Sickle Cell Anemia Patients at Highest Risk for Progression of Chronic Kidney Disease. Trials, record NCT04335721. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04335721
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Voxelotor for Sickle Cell Anemia Patients at Highest Risk for Progression of Chronic Kidney Disease
- NCT number
- NCT04335721
- Status
- Terminated
- Phases
- Phase 1, Phase 2
- Enrollment
- 12 participants, actual
- Lead sponsor
- University of Illinois Chicago
- Conditions
- Sickle Cell Disease, Sickle Cell Nephropathy
- Interventions
- Voxelotor
- First posted
- 2020-04-06
- Last updated
- 2025-04-03
Source ClinicalTrials.gov
Registered outcomes25
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in albuminuria in voxelotor-treated SCA patients compared to the observation patients by a one-sided test | 48 weeks | Albuminuria will be analyzed comparing the mean values from the Week 47 and 48 visits to the mean values from the baseline and screening visits |
| Secondary | Change from the average of the Screening and Baseline values to the Week 47 and Week 48 values in albuminuria | 48 weeks | Proportion of subjects achieving a 25% decline in albuminuria in the voxelotor-treated group compared to the observation group |
| Secondary | Change from the average of the Screening and Baseline values to the Week 47 and Week 48 values in kidney function measure | 48 weeks | 24 hour urine protein |
| Secondary | Change from the average of the Screening and Baseline values to the Week 47 and Week 48 values in In kidney function measure | 48 weeks | 24 hour urine eGFR |
| Secondary | Change from the average of the Screening and Baseline values to the Week 47 and Week 48 values in kidney function measure | 48 weeks | 24 hour urine albumin concentration |
| Secondary | Change from the average of the Screening and Baseline values to the Week 47 and Week 48 values in kidney function measure | 48 weeks | 24 hour serum creatinine |
| Secondary | Change from the average of the Screening and Baseline values to the Week 47 and Week 48 values in Kidney function measure | 48 weeks | 24 hour serum cystatin C |
| Secondary | Change from the average of the Screening and Baseline values to the Week 47 and Week 48 values in Kidney function measure | 48 weeks | 24 hour serum BUN |
| Secondary | Change from the average of the Screening and Baseline values to the Week 47 and Week 48 values in Kidney function measure | 48 weeks | CKD stage |
| Secondary | Change from the average of the Screening and Baseline values to the Week 47 and Week 48 values kidney function measure | 48 weeks | 24 hour urine retinol binding protein |
1 to 10 of 25Source ClinicalTrials.gov
See all 25 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 37254256 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04335721
GET https://conductscience.org/api/trials/v1/NCT04335721/registered?page=2